All In Biotech

Drug Trial Radar · NCT07246044

HD-tDCS for Adolescent Bipolar Depression Targeting S1

High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Targeting the Primary Somatosensory Cortex for Bipolar Depression in Adolescents: A Randomized Double-Blind Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Jiangsu Province Nanjing Brain HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. Participants will be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care. Biological data, including neuroimaging, blood biomarkers, voice and facial features, Photoplethysmography (PPG), Electroencephalography (EEG), and behavioral data, will be collected to explore potential predictors of treatment response.

Conditions

  • Adolescent
  • Bipolar Depression
  • tDCS
  • Primary Somatosensory Cortex
  • Bipolar Disorder Depression

Interventions

  • Active HD-tDCSDevice

    HD-tDCS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.

  • Antipsychotics, mood stabilizers, etc.Drug

    During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.

  • Sham HD-tDCSDevice

    Sham HD-tDCS is administered using the same electrode configuration as the active HD-tDCS condition. During each session, the device ramps up current briefly (typically 30 seconds) to mimic the initial sensation of stimulation, then remains off for the remainder of the 20-minute session. This method produces the same tactile perception as active stimulation without delivering a therapeutic dose of current.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in depressive symptoms assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at Week 2.Time frame: Baseline and after 2 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Nanjing Brain Hospital, Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.